Newborn Screening for Vitamin B₁₂ Deficiency in Germany-Strategies, Results, and Public Health Implications.

Abstract

To evaluate a systematic newborn screening (NBS) strategy for vitamin B₁₂ deficiency. In a prospective single-center NBS study, a systematic screening strategy for vitamin B₁₂ deficiency was developed and evaluated. Tandem-mass spectrometry screening was complemented by 2 second-tier strategies, measuring methylmalonic/3-OH-propionic/methylcitric acid, and homocysteine from dried blood spots. In a cohort of 176 702 children screened over 27 months, 33 children were detected by NBS in whom (maternal) vitamin B₁₂ deficiency was confirmed. Homocysteine was the most sensitive marker for vitamin B₁₂ deficiency, but only combination with a second-tier strategy evaluating methylmalonic acid allowed for detection of all 33 children. Mothers were of various ethnic origins, and 89% adhered to a balanced diet. Treatment in children was performed predominantly by oral vitamin B₁₂ supplementation (84%), and all children remained without clinical symptoms at short-term follow-up. Vitamin B₁₂ deficiency is a treatable condition but can cause severe neurologic sequelae in infants if untreated. The proposed screening strategy is feasible and effective to identify moderate and severe cases of vitamin B₁₂ deficiency. With an incidence of 1:5355 newborns, vitamin B₁₂ deficiency is more frequent than inborn errors of metabolism included in NBS panels. Treatment of vitamin B₁₂ deficiency is easy, and additional benefits can be achieved for previously undiagnosed affected mothers. This supports inclusion of vitamin B₁₂ deficiency into NBS but also stresses the need for increased awareness of vitamin B₁₂ deficiency in caregivers of pregnant women.